ACD856 (NeuroRestore) is a revolutionary molecule: a positive allosteric modulator (PAM) of Trk receptors. No other known synthetic or natural molecule does this.
It is a neurogenesis promoter applicable to neurodegenerative diseases (Alzheimer's, etc.), brain injuries (stroke, etc.), and major depressive disorder (MDD).
ALZECURE PHARMA is behind the molecule, which is expected to enter phase 2A clinical trials this year.
The company's current market capitalization is only $17 million.
They are also working on ACD857.
----------------
COMPETITION
-The psychedelic industry, limited by the narcotic nature of these molecules.
-ALTO Neuroscience, behind NSI-189, a neurogenesis promoter with an unknown mechanism of action (MoA). This company is currently valued at $750 million.
(ACD856 works better according to anecdotal reviews on Reddit)
It is a neurogenesis promoter applicable to neurodegenerative diseases (Alzheimer's, etc.), brain injuries (stroke, etc.), and major depressive disorder (MDD).
ALZECURE PHARMA is behind the molecule, which is expected to enter phase 2A clinical trials this year.
The company's current market capitalization is only $17 million.
They are also working on ACD857.
----------------
COMPETITION
-The psychedelic industry, limited by the narcotic nature of these molecules.
-ALTO Neuroscience, behind NSI-189, a neurogenesis promoter with an unknown mechanism of action (MoA). This company is currently valued at $750 million.
(ACD856 works better according to anecdotal reviews on Reddit)
交易進行
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。